Lipigon (Q3 Review): Topline Before Year-End - Redeye
Redeye comments on Lipigon’s Q3 report. The topline readout of the ongoing phase IIa study of Lipisense in Q4 2025 will be a major catalyst and inform future developments.
ANNONS
Redeye comments on Lipigon’s Q3 report. The topline readout of the ongoing phase IIa study of Lipisense in Q4 2025 will be a major catalyst and inform future developments.
